Archive 2008

EUSA Pharma announces completion of acquisition of Cytogen
9th May 2008. EUSA Pharma announced today that it has completed its acquisition of Cytogen Corporation, following the approval of Cytogen’s shareholders at a special meeting on 8 May

EUSA Pharma divests monoclonal antibody research business and early-stage oncology product
1st May 2008. EUSA Pharma announces that it has divested its monoclonal antibody research business to the French company International Drug Development (IDD). therapeutic research program for acute lymphoblastic leukemia
Concurrently, EUSA divests its recombinant L-asparaginase to the Alizé Pharma Group

EUSA Pharma to Acquire US Specialty Oncology Company Cytogen
11 March 2008. EUSA Pharma to Acquire US Specialty Oncology Company Cytogen, raising $50 million to fund the acquisition and other investments

Novel Rapydan® gains Marketing Authorisation in EU for the Relief of Pain associated with Needle Puncture and Cannulation
25 February 2008. Novel Rapydan® gains Marketing Authorisation in EU for the Relief of Pain associated with Needle Puncture and Cannulation

EUSA Pharma out-licences preclinical-stage human antibody to GlaxoSmithKline for up to $44 million plus royalties
18 February 2008. EUSA Pharma out-licences preclinical-stage human antibody to GlaxoSmithKline for up to $44 million plus royalties

Archive 2007

EUSA Pharma announces $30 million Debt Facility
12 December 2007. EUSA Pharma announces that it has entered into a $30 million debt facility offered by Merrill Lynch Capital.

EUSA Pharma announces successful conclusion of the EMR Procedure for Rapydan®
18 October 2007. EUSA Pharma announces the successful conclusion of the European Mutual Recognition Procedure for Rapydan®. The procedure completed successfully at the “day 90” target date of 9 October 2007.

EUSA Pharma appoints President Europe
3 October 2007. EUSA Pharma appoints Ad van Beysterveldt as President Europe and member of the company’s Executive Committee.

EUSA Pharma appoints Vice President Global Marketing
27 September 2007. EUSA Pharma announces the appointment of Adrian Haigh as
Vice President Global Marketing.

EUSA Pharma acquires Innocoll's Antibiotic and Pain Control Products
23 August 2007. EUSA Pharma today announced the acquisition ofthe assets of Innocoll Inc (“Innocoll”).

EUSA Pharma raises $175m for both the acquisition of OPi SA and the further development of the Company
1 March 2007. EUSA Pharma announces the acquisition of OPi SA (OPi), an integrated biopharmaceutical company.

EUSA Pharma appoint GM for the UK, Ireland and Scandinavia region
28 February 2007. EUSA Pharma announces the appointment of Dr Simon Clough as General Manager for the UK, Ireland and Scandinavia region.

Rapydan gains approval of Swedish Medical Products Agency
26 January 2007. The Swedish Medical Products Agency grants marketing authorisation for Rapydan ®, an advanced topical anaesthetic plaster.

EUSA Pharma appoints Head of supply chain
2 January 2007. EUSA Pharma appoints Paul Davisson as head of supply chain management, Europe.

EUSA Pharma strengthens board
1 January 2007. EUSA Pharma strengthened its board, announcing the appointment of Rolf Stahel as Chairman, William (Bill) Crouse and Göran Ando as non-executive Directors.